Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dengue virus serotype 2, live attenuated
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A live-attenuated vaccine candidate specifically targeting the dengue virus serotype 2 (DENV-2). Developed by researchers at Umeå University and Region Västerbotten, this candidate often utilizes the rDEN2Δ30-7164 strain originally engineered by the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine features a 30-nucleotide deletion in the 3' untranslated region (UTR) of the viral genome, which significantly attenuates the virus while maintaining its ability to replicate sufficiently to induce a robust immune response. It is designed to elicit both neutralizing antibodies and cellular immunity against DENV-2, a serotype frequently associated with severe clinical manifestations such as dengue hemorrhagic fever. Clinical evaluation has primarily focused on assessing safety and immunogenicity in healthy, flavivirus-naive adult populations.
- Other names
- DENV-2 live attenuated vaccineDENV2 live attenuated vaccineDENV 2 live attenuated vaccineDENV2-Delta30DENV-2-Delta30DENV 2-Delta30DENV2-PDK53DENV-2-PDK53DENV 2-PDK53
02
Targets
DENV-2 E (Dengue virus serotype 2 envelope protein)
Beyond the preview
Go deeper on dengue virus serotype 2, live attenuated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dengue virus serotype 2, live attenuated.